
TELA Stock Forecast & Price Target
TELA Analyst Ratings
Bulls say
TELA Bio Inc. has demonstrated strong momentum in its OviTex product line, with unit sales growing 22% in the latest quarter, while OviTex PRS unit sales saw a 3% increase, indicating robust demand for its soft-tissue reconstruction solutions. Despite Q3 revenue growth of 9% year-over-year falling short of expectations, the company is poised for a turnaround with improved sequential performance and strategic enhancements to its commercial leadership, projecting a more conservative yet attainable growth outlook. Additionally, TELA's recent financial maneuvers, including a $13 million equity raise and an upsized debt capacity, have significantly strengthened its balance sheet, extending its cash runway and providing the necessary resources to invest in sales force productivity and product development as it approaches 2026.
Bears say
TELA Bio Inc. has revised its full-year 2025 revenue guidance down to a minimum growth rate of 16%, equating to at least $80.4 million, which marks a decrease from the previously anticipated range of $85.0 million to $88.0 million and represents a substantial slowdown from earlier projections of 23-27% year-over-year growth. Additionally, the company's gross margin of 67.5% fell short of expectations by 200 basis points and decreased by 30 basis points year-over-year, coupled with an operating income miss of approximately $800,000 against previous estimates. This decline in financial outlook, alongside a significant drop in TELA's stock price of over 60% year-to-date, underscores concerns about the company's growth trajectory and operational efficiencies moving forward.
This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
TELA Analyst Forecast & Price Prediction
Start investing in TELA
Order type
Buy in
Order amount
Est. shares
0 shares